Peptides and Obesity: Evaluating Intranasal Administration of Peptides for Therapeutic Potential
Karthi Duraisamy,
Omayma Dlimi,
Amine Bourzam,
Benjamin Lefranc,
Marie‐Anne Le Solliec,
Marie Picot,
Nicolas Chartrel,
Jean A. Boutin,
Olfa Masmoudi,
Sergueï O. Fetissov,
Gaëtan Prévost,
Jérôme Leprince Obesity Reviews
· Wiley
· 2026-11-17
· DOI: 10.1111/obr.70259
Аннотация
ABSTRACT Obesity is a complex global health issue characterized by an imbalance in energy homeostasis and associated with significant health risks, including cardiovascular diseases, diabetes, and cancer. While various therapeutic approaches exist, peptide‐based treatments have emerged as promising candidates due to their specificity and reduced side effects. Because many of the mechanisms are centrally regulated in the brain, effective intervention requires peptides with good brain penetration or alternative delivery strategies. In this context, this review explores the potential of intranasal delivery of therapeutic peptide candidates for obesity management, highlighting its advantages in bypassing the blood–brain barrier, targeting central pathways regulating appetite and energy expenditure, and minimizing systemic exposure, while also considering the translational limitations of this delivery route. The review analyses established and emerging peptides, including leptin, GLP‐1 analogs, and oxytocin, focusing on their central mechanisms of action, specifically their ability to target the brain. It highlights how these peptides regulate energy homeostasis, appetite, and metabolism through direct activation of neural circuits in the hypothalamus, brainstem, and other key regions involved in obesity management. Furthermore, it evaluates the prospects of intranasal peptide therapeutics as an innovative strategy in obesity treatment, addressing both the opportunities and limitations in the context of clinical and preclinical evidence. Continued research and technological advancements are essential to optimize peptide formulations and delivery systems, ensuring efficacy, safety, and patient compliance in combating the obesity epidemic.
Karthi Duraisamy, Omayma Dlimi, Amine Bourzam, Benjamin Lefranc, Marie‐Anne Le Solliec, Marie Picot et al. Peptides and Obesity: Evaluating Intranasal Administration of Peptides for Therapeutic Potential. // Obesity Reviews. – 2026. – DOI: 10.1111/obr.70259. – URL: https://onlinelibrary.wiley.com/doi/10.1111/obr.70259?af=R
Karthi Duraisamy, Omayma Dlimi, Amine Bourzam, Benjamin Lefranc, Marie‐Anne Le Solliec, Marie Picot, Nicolas Chartrel, Jean A. Boutin, Olfa Masmoudi, Sergueï O. Fetissov, Gaëtan Prévost, & Jérôme Leprince (2026). Peptides and Obesity: Evaluating Intranasal Administration of Peptides for Therapeutic Potential. Obesity Reviews. https://doi.org/10.1111/obr.70259
Karthi Duraisamy, et al. “Peptides and Obesity: Evaluating Intranasal Administration of Peptides for Therapeutic Potential.” Obesity Reviews, 2026. doi:10.1111/obr.70259.
@article{Duraisamy2026,
title = {Peptides and Obesity: Evaluating Intranasal Administration of Peptides for Therapeutic Potential},
author = {Duraisamy, Karthi and Dlimi, Omayma and Bourzam, Amine and Lefranc, Benjamin and Solliec, Marie‐Anne Le and Picot, Marie and Chartrel, Nicolas and Boutin, Jean A. and Masmoudi, Olfa and Fetissov, Sergueï O. and Prévost, Gaëtan and Leprince, Jérôme},
journal = {Obesity Reviews},
year = {2026},
doi = {10.1111/obr.70259},
url = {https://onlinelibrary.wiley.com/doi/10.1111/obr.70259?af=R}
}
Abstract Aim Discretionary foods and beverages contribute to poor diet quality and chronic disease. In Australia, intake exceeds dietary guideline recommendations and is unlikely to improve without substantial intervention. We examined...
ABSTRACT Background Ultra‐processed foods (UPFs) are a leading contributor to diet‐related chronic disease and socio‐ecological harm. Despite increasing recognition of these impacts, regulatory responses remain fragmented, focused on...